Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers -- Ignore unavailable to you. Want to Upgrade?

To: s jones who wrote (527)	5/30/1998 2:41:00 PM
From: jbershad	Read Replies (2) \| Respond to of 961

FROM COUGH MIXTURE TO CLEVER SCIENCE <Merrill's Eakin said Biota hoped to test an anti-rhinovirus drug on animals in about a year. ''If they did that, that would be significant, but it's still experimental science,'' he said. Biota plans to use revenues from Relenza, its first drug, to help fund more of its own development work, but a common-cold drug, like the influenza cure, would need massive trials requiring the financial support of a drug company. A company employing just 15 permanent staff, Biota has yet to show a profit after 14 years on the Australian Stock Exchange. But its share price has been on a roller-coaster and at times Biota worried its investors were getting too excited about the progress of its flu work. Biota is also working on drugs to combat cancer and Alzheimer's disease. But for founding investor Alan Woods its work on the flu and common cold are closest to his heart. Woods' grandfather was the creator of ''Woods Great Peppermint Cure'' cough mixture, one of the many brews offered to flu and cold sufferers from the late 1890s. ''It was an exciting venture for us,'' he told Reuters of his initial investment. ''Given the family association, I felt strongly that I wanted to be associated with it.''> ^REUTERS@ Mr. jones What experimental phases has Relenza went through before this. They claim it will soon be released to public. Results? I know I"m missing something here. The new drug is nothing yet This has not been tested on animals. Too early to come to any conclusion. Yes it is supported by major Pharm it seems. Also supported by analyst that works with Tom Kurlak's firm. Poor or unknown track records by all involved. 14 staff members? Wish you the best. Thank you for your article. It is interesting. Lets see how it works out. Jerry